Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/10600
Назва: | Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer |
Автори: | Готько, Євген Степанович T. J. Price A. Cervantès A. F. Sobrero M. Ducreux T. André E. Chan F. Lordick C. J. A. Punt A. H. Strickland G. Wilson T. E. Ciuleanu L. Roman E. Van Cutsem Y. Tian R. Sidhu M. Peeters |
Ключові слова: | antibody, chemotherapy, FOLFIRI, metastatic colorectal cancer, panitumumab |
Дата публікації: | 2014 |
Видавництво: | Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. |
Короткий огляд (реферат): | Background The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab– FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)–FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results One thousand one hundred and eighty-six patients were randomly assigned. In patients with WT KRAS tumors, panitumumab–FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. A trend toward longer OS was observed (median 14.5 versus 12.5 months; HR 0.92 [95% CI 0.78, 1.10]; P = 0.37). Response rates improved from 10% to 36% (P < 0.0001). From post hoc analyses in patients receiving prior oxaliplatin– bevacizumab, panitumumab–FOLFIRI improved PFS (median 6.4 versus 3.7 months; HR 0.58 [95% CI 0.37, 0.90]; P = 0.014). PFS and OS appeared longer for worst-grade skin toxicity of 2–4, versus 0–1 or FOLFIRI. Safety results were as previously reported and consistent with the known toxicities with anti-epidermal growth factor receptor therapy. Conclusions These data confirm the primary efficacy and safety findings of this trial and support panitumumab– FOLFIRI as a second-line treatment of WT KRAS mCRC |
Тип: | Text |
Тип публікації: | Стаття |
URI (Уніфікований ідентифікатор ресурсу): | https://dspace.uzhnu.edu.ua/jspui/handle/lib/10600 |
Розташовується у зібраннях: | Наукові публікації кафедри радіології та онкології |
Файли цього матеріалу:
Файл | Опис | Розмір | Формат | |
---|---|---|---|---|
Final_results_from_a_randomized_phase_3_study_of_FOLFIRI_±_panitumumab_for_second-line_treatment_of_metastatic_colorectal_cancer.PDF | 522.8 kB | Adobe PDF | Переглянути/Відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.